Interpreting treatment trials in schizophrenia patients: Lessons learned from EUFEST

W. Wolfgang Fleischhacker, Eske Derks, Rene S. Kahn

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


There are various procedures to account for missing values in clinical trials. Mixed Model and Last Observation Carried Forward (LOCF) analyses are commonly employed methods. We compared the two methods by reanalysing Positive and Negative Syndrome Scale (PANSS) scores from the European First Episode in Schizophrenia Trial (EUFEST). While the predefined Mixed Model analysis detected no differences between PANSS total score changes in first episode patients treated with haloperidol, amisulpride, quetiapine, olanzapine or ziprasidone over the course of a one year treatment trial, a LOCF analysis revealed significant differences in favor of the new generation antipsychotics over haloperidol. Implications for clinical trial design and the interpretation of such studies are discussed.

Original languageEnglish
Pages (from-to)39-40
Number of pages2
JournalSchizophrenia Research
Issue number1
StatePublished - Jun 2012
Externally publishedYes


Dive into the research topics of 'Interpreting treatment trials in schizophrenia patients: Lessons learned from EUFEST'. Together they form a unique fingerprint.

Cite this